News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Progress In Videregen's Patent Portfolio On Biological Scaffolds For Replacement Organs



11/7/2016 9:45:53 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Applications on novel production methods granted in UK & accepted in Australia

Liverpool, UK - November 7 2016: Videregen Limited, a clinical stage regenerative medicine company developing personalised organ replacements, is pleased to announce progress in the UK and Australia with its intellectual property portfolio on the production of biological scaffolds for organ regeneration and replacement. Patent No GB25060001, which has been granted in the UK, covers the generation of viable implants from intestinal tissue, for use in procedures such as bowel replacements. In Australia, Application No 20142830312 has been accepted, with claims covering production of scaffolds in a range of organ replacements including the trachea which is the company's lead product.

The organ replacement technology Videregen is developing uses tissue from a cadaveric source, from which the donor cells are stripped (to avoid immune reactions), generating a structurally intact scaffold. The scaffold is then repopulated with a recipient patient's own cells prior to implantation.

The scaffold generation method described in the Australian patent application, in which donor organs are perfused with decellularisation solution under negative pressure, is particularly effective in dense tissues such as that of the trachea or larynx. The UK patent covers an improved way to produce a tubular section of intestine with a high level of decellularisation and intact vasculature. This is achieved by perfusion through both the blood vessels and the intestinal lumen.

These patents have been assigned to Videregen by Northwick Park Institute for Medical Research, where the techniques were invented. The company has rights to new regenerative medicine technologies from the Institute, and expects its intellectual property portfolio to be further enhanced through its collaborative research efforts. These include the Innovate UK- and Horizon 2020-funded consortia focused on the trachea replacement clinical trial programme. In addition to its patent portfolio, Videregen has significant know-how covering decellularisation and tissue engineering to commercial standard.

Steve Bloor, CEO of Videregen, said, 'A strong intellectual property portfolio in the major markets worldwide is a prerequisite for the development and commercialisation of our tissue engineered replacement organs for severe medical conditions. These recent developments in our patent estate highlight the innovative nature of our technologies and cement Videregen's position as a leader in regenerative medicine.'

Read at BioSpace.com


comments powered by Disqus
Videregen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES